// App-Quantinova.ai

P2-01-02 : Circulating Tumor Cells (CTC) May Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer Results of the German SUCCESS C Trial

Researchers

Presenter

  • Jaeger BAS

Principal Investigators

  • Andergassen U

  • Fehm T

  • Schneeweiss A

  • Lichtenegger W

  • Beckmann MW

  • Pantel K

  • Sommer HL

  • Friese K

  • Janni W

  • Neugebauer JK

  • Melcher CA

  • Scholz C

  • Hagenbeck C

  • Schueller K

  • Lorenz R

  • Decker T

  • Heinrich G

Medical Centers

  • National Center for Tumor Disease and Department of Gynecology and Obstetrics, University Hospital Heidelberg, Germany

  • Eberhard Karls University, Tubingen, Germany

  • Stat-up Statistische Beratung und Dienstleistung, Munich, Germany

  • Universitaet Erlangen, Germany

  • Praxis Dr. Heinrich, Fuerstenwalde, Germany

  • Gemeinschaftspraxis Lorenz-Hecker-Wesche, Braunschweig, Germany

  • Charite Medical University, Berlin, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Studienzentrum Onkologie Ravensburg, Ravensburg, Germany

  • Klinikum Augsburg, Ludwig-Maximilians-University, Munich, Germany

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fluorescein sodium

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved